TELO TELOMIR PHARMA

-

TELOMIR PHARMA Reported Earnings

Thursday, August 13, 2026 · 12:00 AM ET

TELOMIR PHARMA (TELO) reported a loss of $0.79 per share on revenue of $0.00 million for the . .

Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Telomir Pharmaceuticals Inc. is based in BALTIMORE.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.79)
Earnings Whisper®
Consensus Estimate
Earnings Surprise
Earnings Growth-364.7 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth